Abstract: A high purity aqueous solution of hydroxylamine product is prepared by treating an aqueous solution of hydroxylammonium salt with a base like ammonia at low temperatures. A novel process can be carried out by separating the ammonium salt side product from hydroxylamine with a low temperature filtration and a resin-exchange process. The concentration of the hydroxylamine product is further improved by a safe distillation process that produces a high purity and high concentration hydroxylamine product with reduced risks of explosion.
Type:
Grant
Filed:
January 26, 2004
Date of Patent:
July 8, 2008
Assignee:
San Fu Chemical Company, Ltd.
Inventors:
Kaung-Far Lin, Jin-Fu Chen, Wei Te Lin, Ruey-Shing Chen, Kung-Chin Kuo
Abstract: Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such HuEPO-L-vFc fusion proteins exhibit extended serum half-life and increased biological activities, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.
Type:
Grant
Filed:
December 17, 2004
Date of Patent:
July 31, 2007
Inventors:
Lee-Hwei K. Sun, Bill N. C. Sun, Cecily R. Y. Sun
Abstract: Fc fusion proteins of human G-CSF with increased biological activities relative to rhG-CSF on a molar basis are disclosed. The hG-CSF-L-vFc fusion protein comprises hG-CSF, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such hG-CSF-L-vFc fusion proteins exhibit extended serum half-life and increased biological activities, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.
Type:
Grant
Filed:
March 15, 2004
Date of Patent:
June 19, 2007
Inventors:
Lee-Hwei K. Sun, Bill N. C. Sun, Cecily R. Y. Sun
Abstract: Fc fusion proteins of human G-CSF with increased biological activities relative to rhG-CSF on a molar basis are disclosed. The hG-CSF-L-vFc fusion protein comprises hG-CSF, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such hG-CSF-L-vFc fusion proteins exhibit extended serum half-life and increased biological activities, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.
Type:
Grant
Filed:
March 15, 2004
Date of Patent:
June 5, 2007
Inventors:
Lee-Hwei K. Sun, Bill N. C. Sun, Cecily R. Y. Sun
Abstract: Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such HuEPO-L-vFc fusion proteins exhibit extended serum half-life and increased biological activities, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.
Type:
Grant
Filed:
December 17, 2004
Date of Patent:
April 18, 2006
Inventors:
Lee-Hwei K. Sun, Bill N. C. Sun, Cecily R. Y. Sun
Abstract: Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such HuEPO-L-vFc fusion proteins exhibit extended serum half-life and increased biological activities, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.
Type:
Grant
Filed:
August 17, 2001
Date of Patent:
May 31, 2005
Inventors:
Lee-Hwei K. Sun, Bill N. C. Sun, Cecily R. Y. Sun